Patents by Inventor Martina BENESOVA

Martina BENESOVA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer
    Patent number: 11951190
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: April 9, 2024
    Assignee: NOVARTIS AG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
    Patent number: 11931430
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: March 19, 2024
    Assignee: NOVARTIS AG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • 18F - TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND THEIR USE AS IMAGING AGENTS FOR PROSTATE CANCER
    Publication number: 20230295092
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.
    Type: Application
    Filed: March 17, 2023
    Publication date: September 21, 2023
    Inventors: Jens Cardinale, Martin Schaefer, Klaus Kopka, Matthias Eder, Ulrike Bauder-Wuest, Michael Eisenhut, Martina Benesova, Uwe Haberkorn, Frederik L. Giesel
  • Double-labeled probe for molecular imaging and use thereof
    Patent number: 11638765
    Abstract: The present invention relates to a compound of a pharmaceutically acceptable salt thereof of formula (I) wherein (A) is at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; (C) a dye moiety; x1 is a spacer or a chemical single bond covalently connecting (A) to the rest of the molecule; x2 is a spacer or a chemical single bond covalently connecting (C) to the rest of the molecule. The invention further relates to compositions comprising said compounds as well as a method for detecting neoplastic cells in a sample in vitro with the aid of the compounds or composition.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: May 2, 2023
    Assignees: Deutsches Krebsforschungszentrum, Ruprecht-Karls -Uni versitaet Heidelberg
    Inventors: Matthias Eder, Klaus Kopka, Martin Schaefer, Ulrike Bauder-Wuest, Uwe Haberkorn, Ann-Christin Eder, Jens Cardinale, Martina Benesova
  • PSMA-binding agents and uses thereof
    Patent number: 11629201
    Abstract: The present invention provides novel compounds that are useful as radiopharmaceuticals, imaging agents and for treatment of cancer.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: April 18, 2023
    Assignees: ITM Isotope Technologies Munich SE, Paul Scherrer Institut
    Inventors: Martina Benesova, Cristina Müller, Christoph Umbricht, Roger Schibli, Konstantin Zhernosekov
  • SYSTEM AND METHOD FOR ADAPTING TEXT-BASED DATA STRUCTURES TO TEXT SAMPLES
    Publication number: 20230080789
    Abstract: A system and method for customizing multimedia content using text-based data structures adapted to text samples. A method includes dividing a text sample into segments of approximately the same size. A unique word occurring exactly once in two or more of the segments is identified. Neighboring words within a threshold distance of the unique word in each of the segments are identified. A first sentiment is determined based on the neighboring words for the unique word. A text skeleton is modified by inserting the unique word into the location in the structured dataset based on the determined first sentiment, wherein the text skeleton is a structured dataset including a location having a designated second sentiment matching the first sentiment. The modified text skeleton is inserted into a multimedia content item in order to create a customized multimedia content item for the text sample.
    Type: Application
    Filed: June 27, 2022
    Publication date: March 16, 2023
    Applicant: Univerzita Palackého v Olomouci
    Inventors: Dan FALTÝNEK, Martina BENESOVÁ, Vladimír MATLACH, Ondrej KUCERA
  • NOVEL TUMOR ANTIGEN BINDING AGENTS AND USES THEREOF
    Publication number: 20220024882
    Abstract: The present invention provides compounds according to General Formula (1)(i) or (1)(ii): wherein A is a diagnostic or therapeutic agent comprising a binding site for a tumor antigen, and the spacer comprises at least one C—N bond.
    Type: Application
    Filed: November 28, 2019
    Publication date: January 27, 2022
    Inventors: Martina Benesova, Cristina Müller, Christoph Umbricht, Roger Schibli, Konstantin Zhernosekov, Luisa Maria Deberle
  • USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20210283279
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: January 7, 2021
    Publication date: September 16, 2021
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
    Patent number: 11045564
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: June 29, 2021
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20210177996
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: December 3, 2020
    Publication date: June 17, 2021
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • 18F - TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND THEIR USE AS IMAGING AGENTS FOR PROSTATE CANCER
    Publication number: 20210053922
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 25, 2021
    Inventors: Jens CARDINALE, Martin SCHAEFER, Klaus KOPKA, Matthias EDER, Ulrike BAUDER-WUEST, Michael EISENHUT, Martina BENESOVA, Uwe HABERKORN, Frederik L. GIESEL
  • NOVEL PSMA-BINDING AGENTS AND USES THEREOF
    Publication number: 20210009715
    Abstract: The present invention provides novel compounds that are useful as radiopharmaceuticals, imaging agents and for treatment of cancer.
    Type: Application
    Filed: May 24, 2018
    Publication date: January 14, 2021
    Inventors: Martina Benesova, Cristina Müller, Christoph Umbricht, Roger Schibli, Konstantin Zhernosekov
  • A DOUBLE-LABELED PROBE FOR MOLECULAR IMAGING AND USE THEREOF
    Publication number: 20200353109
    Abstract: The present invention relates to a compound of a pharmaceutically acceptable salt thereof of formula (I) wherein (A) is at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; (C) a dye moiety; x1 is a spacer or a chemical single bond covalently connecting (A) to the rest of the molecule; x2 is a spacer or a chemical single bond covalently connecting (C) to the rest of the molecule. The invention further relates to compositions comprising said compounds as well as a method for detecting neoplastic cells in a sample in vitro with the aid of the compounds or composition.
    Type: Application
    Filed: November 20, 2018
    Publication date: November 12, 2020
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHAEFER, Ulrike BAUDER-WUEST, Uwe HABERKORN, Ann-Christin EDER, Jens CARDINALE, Martina BENESOVA
  • 18F—tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer
    Patent number: 10815200
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: October 27, 2020
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
    Inventors: Jens Cardinale, Martin Schaefer, Klaus Kopka, Matthias Eder, Ulrike Bauder-Wuest, Michael Eisenhut, Martina Benesova, Uwe Haberkorn, Frederik L. Giesel
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20190374660
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: August 26, 2019
    Publication date: December 12, 2019
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe HABERKORN, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
    Patent number: 10471160
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: November 12, 2019
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Uwe Haberkorn, Michael Eisenhut, Walter Mier, Martina Benesova, Hans-Christian Kliem, Clemens Kratochwil
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20190336622
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: July 12, 2019
    Publication date: November 7, 2019
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe HABERKORN, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
    Patent number: 10398791
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: September 3, 2019
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Uwe Haberkorn, Michael Eisenhut, Walter Mier, Martina Benesova
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20190060491
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: August 28, 2018
    Publication date: February 28, 2019
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe HABERKORN, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20190008988
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: July 18, 2018
    Publication date: January 10, 2019
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Uwe HABERKORN, Michael EISENHUT, Walter MIER, Martina BENESOVA, Hans-Christian KLIEM, Clemens KRATOCHWIL